

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	25.0	112.0	(74.4-161.9)	Male	21	16.7	125.9	(77.9-192.5)
Female	10	9.0	111.4	(53.3-204.8)	Female	18	12.7	141.3	(83.7-223.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.2	154.9	(66.7-305.2)	Male	8	4.1	193.3	(83.2-381.0)
Female	3	4.1	nc	(nc-nc)	Female	5	3.0	168.9	(54.4-394.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	19	14.2	133.9	(80.6-209.1)
Female	102	96.0	106.2	(86.6-128.9)	Female	13	11.6	112.0	(59.6-191.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.9	126.9	(40.9-296.1)	Male	4	10.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	8	4.6	173.9	(74.9-342.7)
Male	27	32.4	83.3	(54.9-121.3)	<u>Ovary</u>				
Female	36	29.0	124.1	(86.9-171.7)	Female	5	9.2	54.1	(17.4-126.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.1	70.5	(22.7-164.5)	Male	9	8.1	111.7	(51.0-212.1)
Female	3	1.7	nc	(nc-nc)	Female	7	7.8	89.3	(35.8-184.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	102	105.3	96.9	(79.0-117.6)
Female	3	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.0	99.5	(36.3-216.6)
Male	12	13.9	86.4	(44.6-151.0)	Female	5	3.2	156.3	(50.4-364.8)
Female	8	7.8	102.2	(44.0-201.4)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.6	167.4	(61.1-364.4)
Male	1	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
<u>Leukemia</u>					Female	17	16.1	105.5	(61.4-168.9)
Male	14	8.9	158.2	(86.4-265.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.4	78.0	(25.1-182.0)	Female	26	22.7	114.6	(74.9-168.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	7.1	126.4	(57.7-239.9)	Male	368	353.6	104.1	(93.7-115.3)
Female	1	2.2	nc	(nc-nc)	Female	375	325.0	115.4	(104.0-127.7)
<u>Lung and Bronchus</u>									
Male	58	48.0	120.9	(91.8-156.3)					
Female	49	46.6	105.3	(77.9-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;